Finance

Beta
Lists
EYPT:NASDAQ
EyePoint Inc
11,50 US$
-2,42%
(-0,28) 1D
8 ივნ, 13:25:23 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EYPT...
Open
11,90 US$
High
11,99 US$
Low
11,46 US$
Mkt. cap
964,17 მლნ.
Avg. vol.
901,62 ათ.
Volume
315,36 ათ.
52-wk high
19,11 US$
52-wk low
7,94 US$
EPS
-3,50 US$
Beta
1,72
Shares outstanding
83,84 მლნ.
No. of employees
214
Open
11,90 US$
High
11,99 US$
Low
11,46 US$
Mkt. cap
964,17 მლნ.
Avg. vol.
901,62 ათ.
Volume
315,36 ათ.
52-wk high
19,11 US$
52-wk low
7,94 US$
EPS
-3,50 US$
Beta
1,72
Shares outstanding
83,84 მლნ.
No. of employees
214
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to EYPT in the past 3 months
Strong Buy
Buy
9
Hold
0
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for EYPT in the last 3 months.
Highest
Current 11,50 US$
68,00 US$ (+491,56%)
Average
36,78 US$ (+219,97%)
Lowest
20,00 US$ (+73,99%)
News stories
From sources across the web
Profile
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc. Wikipedia
About EyePoint Inc
CEO-
Employees214
Founded2000
HeadquartersWatertown, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websiteeyepoint.bio
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
5,33 მლნ.
966,00 ათ.
620,00 ათ.
696,00 ათ.
Cost of goods sold
54,65 მლნ.
47,46 მლნ.
58,58 მლნ.
71,67 მლნ.
Cost of revenue
54,65 მლნ.
47,46 მლნ.
58,58 მლნ.
71,67 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,91 მლნ.
15,53 მლნ.
12,39 მლნ.
16,26 მლნ.
Operating expense
12,91 მლნ.
15,53 მლნ.
12,39 მლნ.
16,26 მლნ.
Total operating expenses
67,56 მლნ.
62,99 მლნ.
70,96 მლნ.
87,92 მლნ.
Operating income
-62,23 მლნ.
-62,02 მლნ.
-70,34 მლნ.
-87,23 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-59,33 მლნ.
-59,73 მლნ.
-67,42 მლნ.
-84,88 მლნ.
EBT excluding unusual items
-59,33 მლნ.
-59,73 მლნ.
-67,42 მლნ.
-84,88 მლნ.
Income tax expense
93,00 ათ.
-
186,00 ათ.
-50,00 ათ.
Effective tax rate
-0,16%
-
-0,28%
0,06%
Other operating expenses
-
-
-
-
Net income
-59,43 მლნ.
-59,73 მლნ.
-67,61 მლნ.
-84,83 მლნ.
Net profit margin
-1 114,31%
-6 183,44%
-10 904,68%
-12 188,51%
Earnings per share
-0,85
-0,85
-0,81
-0,99
Interest and investment income
2,89 მლნ.
2,29 მლნ.
2,96 მლნ.
2,34 მლნ.
Interest expense
-
-
-33,00 ათ.
-
Net interest expenses
2,89 მლნ.
2,29 მლნ.
2,92 მლნ.
2,34 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-61,69 მლნ.
-61,45 მლნ.
-69,65 მლნ.
-86,59 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer